All
ANI Pharmaceuticals completes acquisition of Alimera Sciences
September 17th 2024The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.
Study: 100x improvement in sight detected after gene therapy trial
September 13th 2024According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.
Boehringer Ingelheim to advance potential new treatment for GA following Phase 1 results
September 10th 2024BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.